Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1998 Nov;79(5):452–455. doi: 10.1136/adc.79.5.452

Primary pulmonary hypertension in childhood

S Haworth 1
PMCID: PMC1717735  PMID: 10193263

Full Text

The Full Text of this article is available as a PDF (66.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asherson R. A., Higenbottam T. W., Dinh Xuan A. T., Khamashta M. A., Hughes G. R. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol. 1990 Oct;17(10):1292–1298. [PubMed] [Google Scholar]
  2. Barst R. J., Flaster E. R., Menon A., Fotino M., Morse J. H. Evidence for the association of unexplained pulmonary hypertension in children with the major histocompatibility complex. Circulation. 1992 Jan;85(1):249–258. doi: 10.1161/01.cir.85.1.249. [DOI] [PubMed] [Google Scholar]
  3. Barst R. J. Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension. Chest. 1986 Apr;89(4):497–503. doi: 10.1378/chest.89.4.497. [DOI] [PubMed] [Google Scholar]
  4. Barst R. J., Rubin L. J., Long W. A., McGoon M. D., Rich S., Badesch D. B., Groves B. M., Tapson V. F., Bourge R. C., Brundage B. H. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1;334(5):296–301. doi: 10.1056/NEJM199602013340504. [DOI] [PubMed] [Google Scholar]
  5. Barst R. J., Rubin L. J., McGoon M. D., Caldwell E. J., Long W. A., Levy P. S. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994 Sep 15;121(6):409–415. doi: 10.7326/0003-4819-121-6-199409150-00003. [DOI] [PubMed] [Google Scholar]
  6. Barst R. J. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin. Heart. 1997 Apr;77(4):299–301. doi: 10.1136/hrt.77.4.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bowyer J. J., Busst C. M., Denison D. M., Shinebourne E. A. Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J. 1986 Apr;55(4):385–390. doi: 10.1136/hrt.55.4.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Christman B. W., McPherson C. D., Newman J. H., King G. A., Bernard G. R., Groves B. M., Loyd J. E. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992 Jul 9;327(2):70–75. doi: 10.1056/NEJM199207093270202. [DOI] [PubMed] [Google Scholar]
  9. D'Angelo A., Della Valle P., Crippa L., Pattarini E., Grimaldi L. M., Viganò D'Angelo S. Brief report: autoimmune protein S deficiency in a boy with severe thromboembolic disease. N Engl J Med. 1993 Jun 17;328(24):1753–1757. doi: 10.1056/NEJM199306173282405. [DOI] [PubMed] [Google Scholar]
  10. Eisenberg P. R., Lucore C., Kaufman L., Sobel B. E., Jaffe A. S., Rich S. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation. 1990 Sep;82(3):841–847. doi: 10.1161/01.cir.82.3.841. [DOI] [PubMed] [Google Scholar]
  11. Fuster V., Steele P. M., Edwards W. D., Gersh B. J., McGoon M. D., Frye R. L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984 Oct;70(4):580–587. doi: 10.1161/01.cir.70.4.580. [DOI] [PubMed] [Google Scholar]
  12. Gurtner H. P. Aminorex and pulmonary hypertension. A review. Cor Vasa. 1985;27(2-3):160–171. [PubMed] [Google Scholar]
  13. Hervé P., Launay J. M., Scrobohaci M. L., Brenot F., Simonneau G., Petitpretz P., Poubeau P., Cerrina J., Duroux P., Drouet L. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995 Sep;99(3):249–254. doi: 10.1016/s0002-9343(99)80156-9. [DOI] [PubMed] [Google Scholar]
  14. Jones D. A., Benjamin C. W., Linseman D. A. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol. 1995 Nov;48(5):890–896. [PubMed] [Google Scholar]
  15. Kerstein D., Levy P. S., Hsu D. T., Hordof A. J., Gersony W. M., Barst R. J. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation. 1995 Apr 1;91(7):2028–2035. doi: 10.1161/01.cir.91.7.2028. [DOI] [PubMed] [Google Scholar]
  16. Langleben D. Familial primary pulmonary hypertension. Chest. 1994 Feb;105(2 Suppl):13S–16S. doi: 10.1378/chest.105.2_supplement.13s. [DOI] [PubMed] [Google Scholar]
  17. Loyd J. E., Butler M. G., Foroud T. M., Conneally P. M., Phillips J. A., 3rd, Newman J. H. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med. 1995 Jul;152(1):93–97. doi: 10.1164/ajrccm.152.1.7599869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Loyd J. E., Primm R. K., Newman J. H. Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis. 1984 Jan;129(1):194–197. doi: 10.1164/arrd.1984.129.1.194. [DOI] [PubMed] [Google Scholar]
  19. Mark E. J., Patalas E. D., Chang H. T., Evans R. J., Kessler S. C. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med. 1997 Aug 28;337(9):602–606. doi: 10.1056/NEJM199708283370904. [DOI] [PubMed] [Google Scholar]
  20. McLaughlin V. V., Genthner D. E., Panella M. M., Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998 Jan 29;338(5):273–277. doi: 10.1056/NEJM199801293380501. [DOI] [PubMed] [Google Scholar]
  21. Morse J. H., Barst R. J., Fotino M. Familial pulmonary hypertension: immunogenetic findings in four Caucasian kindreds. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):787–792. doi: 10.1164/ajrccm/145.4_Pt_1.787. [DOI] [PubMed] [Google Scholar]
  22. Nichols W. C., Koller D. L., Slovis B., Foroud T., Terry V. H., Arnold N. D., Siemieniak D. R., Wheeler L., Phillips J. A., 3rd, Newman J. H. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet. 1997 Mar;15(3):277–280. doi: 10.1038/ng0397-277. [DOI] [PubMed] [Google Scholar]
  23. Polos P. G., Wolfe D., Harley R. A., Strange C., Sahn S. A. Pulmonary hypertension and human immunodeficiency virus infection. Two reports and a review of the literature. Chest. 1992 Feb;101(2):474–478. doi: 10.1378/chest.101.2.474. [DOI] [PubMed] [Google Scholar]
  24. Polos P. G., Wolfe D., Harley R. A., Strange C., Sahn S. A. Pulmonary hypertension and human immunodeficiency virus infection. Two reports and a review of the literature. Chest. 1992 Feb;101(2):474–478. doi: 10.1378/chest.101.2.474. [DOI] [PubMed] [Google Scholar]
  25. Rhodes J., Barst R. J., Garofano R. P., Thoele D. G., Gersony W. M. Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. J Am Coll Cardiol. 1991 Dec;18(7):1738–1744. doi: 10.1016/0735-1097(91)90513-9. [DOI] [PubMed] [Google Scholar]
  26. Rich S., Dantzker D. R., Ayres S. M., Bergofsky E. H., Brundage B. H., Detre K. M., Fishman A. P., Goldring R. M., Groves B. M., Koerner S. K. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987 Aug;107(2):216–223. doi: 10.7326/0003-4819-107-2-216. [DOI] [PubMed] [Google Scholar]
  27. Riley M. S., Pórszász J., Miranda J., Engelen M. P., Brundage B., Wasserman K. Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis. Chest. 1997 Jan;111(1):44–50. doi: 10.1378/chest.111.1.44. [DOI] [PubMed] [Google Scholar]
  28. Stewart D. J., Levy R. D., Cernacek P., Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991 Mar 15;114(6):464–469. doi: 10.7326/0003-4819-114-6-464. [DOI] [PubMed] [Google Scholar]
  29. Weir E. K., Reeve H. L., Huang J. M., Michelakis E., Nelson D. P., Hampl V., Archer S. L. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation. 1996 Nov 1;94(9):2216–2220. doi: 10.1161/01.cir.94.9.2216. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES